ALXO - Dosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study

ALX Oncology (ALXO) has dosed the first patient in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148 with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome ((MDS)).The Phase 1 part of the study is expected to characterize the safety of ALX148 in combination with azacitidine in patients with relapsed/refractory or previously untreated higher-risk MDS. Upon completion of the Phase 1, the Phase 2 part of the study will be initiated to evaluate the efficacy of the combination in patients with previously untreated higher-risk MDS.The company also has an ongoing Phase 1 trial evaluating ALX148 in combination with other anti-cancer agents in over 150 patients with various malignancies.

For further details see:

Dosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study